The US FDA has granted clearance to SpliceBio’s IND application to begin the trial of SB-007, designed for Stargardt disease treatment.

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.

Mesoblast Limited recently announced positive Phase III trial results in the European Journal of Heart Failure.

SK bioscience has gained Australia’s Human Research Ethics Committee (HREC) approval to begin Phase I/II clinical trials of GBP560.

Trevi has announced that its Phase IIb trial of Haduvio in treating IPF subjects with chronic cough will continue without sample size change.

Satellos Bioscience has dosed the first subject with DMD in a Phase Ib trial of its oral small molecule drug candidate, SAT-3247.

The Phase III study saw the drug able to cut risk of death by 38% with imlunestrant alone, and down so far as 43% with Verzenio.

Early results from Blue Lake trial found the vaccine to be safe, tolerated and able to cut the chance of contracting the infection.

Enlivex has gained approval from the Israeli regulator approval to commence a Phase I trial of Allocetra in people with TMJ osteoarthritis.

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were presented.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.